MAX-40279 hemiadipate is a dual potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate may be used for studying acute myeloid leukemia (AML) (information disclosed in patent WO2021180032A1).

Physicochemical Properties

Molecular Formula	C28H33FN6O5S
Molecular Weight	584.66
Exact Mass	584.221
CAS #	2388506-44-1
Related CAS #	MAX-40279;2070931-57-4;MAX-40279 hemifumarate;2388506-43-0;MAX-40279 hydrochloride;2388506-51-0
PubChem CID	157608770
Appearance	Off-white to light yellow solid powder
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	10
Heavy Atom Count	41
Complexity	712
Defined Atom Stereocenter Count	0
SMILES	C(CC(=O)O)CCC(=O)O.CC1SC2=CN=C(NC3C=NN(C4CCNCC4)C=3)N=C2C=1C1C=CC(F)=CC=1OC
InChi Key	CKQKESWOXOJTTB-UHFFFAOYSA-N
InChi Code	InChI=1S/C22H23FN6OS.C6H10O4/c1-13-20(17-4-3-14(23)9-18(17)30-2)21-19(31-13)11-25-22(28-21)27-15-10-26-29(12-15)16-5-7-24-8-6-16;7-5(8)3-1-2-4-6(9)10/h3-4,9-12,16,24H,5-8H2,1-2H3,(H,25,27,28);1-4H2,(H,7,8)(H,9,10)
Chemical Name	7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-(1-piperidin-4-ylpyrazol-4-yl)thieno[3,2-d]pyrimidin-2-amine;hexanedioic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	FLT3 and FGFR[1]
References	[1]. Novel Therapeutic Methods. Patent WO2021180032A1.

Solubility Data

Solubility (In Vitro)

DMSO: 25 mg/mL (42.76 mM) DMF: 10 mg/mL (17.10 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (3.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.7104 mL	8.5520 mL	17.1040 mL
	5 mM	0.3421 mL	1.7104 mL	3.4208 mL
	10 mM	0.1710 mL	0.8552 mL	1.7104 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.